Skip to content

Pharmacology, biochemistry, and behavior

ISSN 1873-5177

71 papers in the library · 2,663 citations · publishing 1975-2026

Papers

Do functional relationships exist between 5-HT1A and 5-HT2 receptors?

Pharmacology, biochemistry, and behavior August 1, 1990 N A Darmani, B R Martin, U Pandey et al. 245 citations

In mice, the drug (+/-)-DOI, which activates 5-HT2 receptors, causes a head-twitch response that increases with dose. The (-) isomer of DOI is twice as potent as the (+) isomer. Selective 5-HT2 blockers (ketanserin and spiperone) reduce this response in a dose-dependent way. A nonselective 5-HT agonist (5-MeO DMT) and a 5-HT1A-selective agonist (8-OH-DPAT) also reduce the response, but a 5-HT1B/5-HT1C-selective agonist (TFMPP) does not. The authors propose that 5-HT1A receptors inhibit the 5-HT2 receptor-mediated head-twitch response.

Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome.

Pharmacology, biochemistry, and behavior June 1, 1986 L M Smith, S J Peroutka 245 citations

Four drugs that bind to the same serotonin receptor subtype (5-HT1A) produce different behavioral effects in rats. 8-OH-DPAT, 5-MeODMT, buspirone, and isapirone all potently inhibit 3H-8-OH-DPAT binding to rat brain membranes (Ki values = 1.9-13 nM). However, only 8-OH-DPAT and 5-MeODMT induce forepaw treading, head-weaving, and tremor, while buspirone and isapirone actually block those behaviors when given alongside the full agonists. All four drugs induce hindlimb abduction, flattened body posture, and Straub tail. The findings suggest that specific components of the serotonin behavioral syndrome are mediated by 5-HT1A receptors.

Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.

Pharmacology, biochemistry, and behavior January 1, 2006 W E Fantegrossi, A W Harrington, C L Kiessel et al. 144 citations

5-MeO-DIPT, a hallucinogenic drug similar to DMT, produced head-twitch responses in mice, an effect blocked by a serotonin 2A receptor antagonist. In rats trained to recognize LSD, 5-MeO-DIPT partially substituted for LSD (75% generalization) and suppressed response rates in a dose-dependent way; this effect was abolished by a 5-HT2A antagonist but not by a 5-HT1A antagonist. The drug showed micromolar affinity for 5-HT2A and 5-HT2C receptors and much higher affinity for 5-HT1A receptors in rat brain tissue. The results indicate that the 5-HT2A receptor is a key site of action for 5-MeO-DIPT, despite its in vitro selectivity for the 5-HT1A receptor.

Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder?

Pharmacology, biochemistry, and behavior October 1, 1991 E Yadin, E Friedman, W H Bridger 137 citations

Serotonergic drugs that activate certain receptors (5-HT1A) disrupt spontaneous alternation in rats, a behavior that may model the perseveration and indecisiveness seen in obsessive-compulsive disorder (OCD). Food-deprived rats given repeated choices in a T-maze normally alternate between goal boxes. Both the nonselective 5-HT agonist 5-MeODMT and the more selective 5-HT1A agonist 8-OH-DPAT reduced this alternation. Chronic treatment with the selective serotonin reuptake inhibitor fluoxetine protected against the disruption caused by 5-MeODMT. The findings suggest that serotonergic manipulation of spontaneous alternation could serve as a simple animal model for certain OCD symptoms.

Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats.

Pharmacology, biochemistry, and behavior November 1, 1995 A H Rezvani, D H Overstreet, Y W Lee 136 citations

Ibogaine, injected into the abdomen or given orally, but not under the skin, reduced alcohol intake in alcohol-preferring, Fawn-Hooded, and alcohol-accepting rats. The effect was dose-dependent and did not diminish with repeated oral doses over five days. Ibogaine did not affect blood alcohol levels or food and water intake. The results suggest that ibogaine or its metabolites may reduce alcohol consumption by modulating brain chemicals involved in alcohol intake regulation, though the exact mechanism is not fully understood.

The effects of 8-hydroxy-2-(di-n-propylamino)tetralin and other serotonergic agonists on performance in a radial maze: a possible role for 5-HT1A receptors in memory.

Pharmacology, biochemistry, and behavior August 1, 1987 J C Winter, D T Petti 128 citations

In a radial maze task, rats given various serotonergic drugs showed dose-related declines in response rate, except for a low dose of 8-OH-DPAT that increased responding. LSD, RU 24969, and 8-OH-DPAT also reduced efficiency, with 8-OH-DPAT being the most potent, producing efficiencies of 61%, 53%, and 44% at 0.3, 1.0, and 3.0 mg/kg, respectively. Given 8-OH-DPAT's selectivity for 5-HT1A receptors, the high density of these receptors in the hippocampus, and their reduction in Alzheimer's disease, the authors suggest this serotonin receptor subtype may play a role in memory.

Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.

Pharmacology, biochemistry, and behavior June 1, 2003 Isabelle M. Maisonneuve, Stanley D. Glick 109 citations

18-Methoxycoronaridine (18-MC), a synthetic compound related to iboga, reduces self-administration of multiple addictive drugs in animal models. It decreased intravenous morphine, cocaine, methamphetamine, and nicotine self-administration, as well as oral alcohol and nicotine intake, and eased opioid withdrawal signs, without affecting responding for a nondrug reinforcer (water) or causing apparent toxicity. 18-MC also blocked sensitized dopamine responses to morphine and cocaine in the nucleus accumbens. Receptor studies identified it as a potent antagonist at alpha3beta4 nicotinic receptors. Low-dose combinations of 18-MC with other alpha3beta4 antagonists reduced drug self-administration at otherwise ineffective doses. The findings suggest that alpha3beta4 nicotinic receptor antagonists may offer a novel, broad-spectrum treatment for addiction.

Plant derivatives in the treatment of alcohol dependency.

Pharmacology, biochemistry, and behavior June 1, 2003 Amir H Rezvani, David H Overstreet, Marina Perfumi et al. 95 citations

A review of studies in alcohol-preferring rats shows that extracts from St. John's wort, kudzu, and ibogaine, as well as purified compounds from these plants (puerarin, daidzin, daidzein, and ibogaine analogs), dose-dependently reduce alcohol intake after a single dose, with minimal effects on food intake. Puerarin and St. John's wort extract also remain effective with repeated dosing. The compounds appear to work by modulating multiple brain systems involved in drinking, though their exact mechanisms are not fully understood. Whether these compounds become treatments for alcoholism depends on future clinical trials.

Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats.

Pharmacology, biochemistry, and behavior December 1, 2009 Aashish S. Morani, Bronwyn Kivell, Thomas E. Prisinzano et al. 91 citations

Pretreatment with several kappa-opioid receptor agonists, including salvinorin A (Sal A), the active compound in Salvia divinorum, reduced cocaine-induced drug-seeking in rats. After learning to self-administer cocaine, rats underwent extinction and then received a cocaine priming injection. Cocaine-induced reinstatement of drug-seeking was attenuated by U69593, U50488H, spiradoline, and Sal A. Sal A did not affect sucrose-reinforced responding or cocaine-induced hyperactivity, suggesting its effects are specific to drug-seeking. These findings indicate that Sal A, like other kappa-opioid agonists, can suppress cocaine-seeking behavior.

The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.

Pharmacology, biochemistry, and behavior January 1, 2000 J C Winter, R A Filipink, D Timineri et al. 80 citations

In rats trained to recognize the effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or (-)-2,5-dimethoxy-4-methylamphetamine (DOM), blocking specific serotonin receptors revealed which receptors mediate each drug's effects. Blocking 5-HT1A receptors strongly reduced 5-MeO-DMT's effects, while blocking 5-HT2 receptors had little effect. Conversely, DOM's effects were blocked by a 5-HT2 antagonist but not by 5-HT1A antagonists. 5-MeO-DMT partially mimicked DOM only when given subcutaneously, and this required both 5-HT1A and 5-HT2 receptor involvement. The findings indicate that 5-MeO-DMT's effects rely mainly on 5-HT1A receptors, but it also activates 5-HT2 receptors, a component revealed in animals trained with the 5-HT2-selective drug DOM.

Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats.

Pharmacology, biochemistry, and behavior October 1, 1997 A H Rezvani, D H Overstreet, Y Yang et al. 78 citations

A single injection of 18-methoxycoronaridine (18-MC), a nontoxic ibogaine analogue, dose dependently reduced alcohol consumption and preference in alcohol-preferring rats, while water intake increased correspondingly. Only the highest dose (40 mg/kg) also decreased food intake. The mechanism by which 18-MC suppresses alcohol intake is not yet fully understood but may involve modulation of neurotransmitters that regulate alcohol consumption.

Ibogaine reduces preference for cocaine consumption in C57BL/6By mice.

Pharmacology, biochemistry, and behavior January 1, 1994 H Sershen, A Hashim, A Lajtha 75 citations

Male C57BL/6By mice developed a preference for cocaine after forced exposure to it in drinking water. When given a choice, they consumed 71% of their fluid from the cocaine solution. Ibogaine administration reduced cocaine preference to 41% and daily cocaine intake by 38% for at least five days. Cocaine-challenged mice previously exposed to cocaine showed increased locomotor activity and stereotypy, which were reduced after ibogaine treatment. Brain cocaine levels were about 25% higher in ibogaine-treated mice, suggesting ibogaine may alter cocaine pharmacokinetics.

Psilocybin-induced stimulus control in the rat.

Pharmacology, biochemistry, and behavior October 1, 2007 J C Winter, K C Rice, D J Amorosi et al. 73 citations

Psilocybin produces a complex internal cue in rats that depends partly, but not entirely, on the 5-HT2A serotonin receptor. Blocking the 5-HT2A receptor with M100907 only partially reduced the drug's effect, while blocking the 5-HT1A/7 receptor or the dopamine D2 receptor had no effect. Rats trained to recognize psilocybin also recognized other hallucinogens such as LSD, psilocin, and DOM, and partially recognized mescaline and 2C-T-7. LSD and MDMA partly substituted for psilocybin, and those effects were fully blocked by M100907. Unlike the related hallucinogen 5-MeO-DMT, psilocybin's effects do not involve the 5-HT1A receptor.

Suppressive effect of mitragynine on the 5-methoxy-N,N-dimethyltryptamine-induced head-twitch response in mice.

Pharmacology, biochemistry, and behavior January 1, 1997 K Matsumoto, M Mizowaki, H Takayama et al. 60 citations

Mitragynine, a compound from kratom leaves, suppresses head-twitch responses in mice induced by a serotonin receptor agonist, similar to a known 5-HT2A receptor antagonist. The effect was dose-dependent and not altered by depleting serotonin or dopamine systems, but was reduced by drugs that block alpha-2 adrenoceptors. This suggests mitragynine acts through stimulation of postsynaptic alpha-2 adrenoceptors, blockade of 5-HT2A receptors, or both.

Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism.

Pharmacology, biochemistry, and behavior August 1, 1997 S M Pearl, L B Hough, D L Boyd et al. 58 citations

Ibogaine, a substance studied for antiaddictive properties, produces stronger behavioral effects in female rats than in males, correlating with higher ibogaine levels in their brains and plasma. Five hours after a 40 mg/kg dose, ibogaine antagonized morphine-induced locomotor activity only in females. At 19 hours after 10-60 mg/kg ibogaine or one hour after 5-40 mg/kg noribogaine (a metabolite), antagonism was greater in females. Brain and plasma levels of ibogaine and noribogaine were higher in females given the same dose. Levels were much lower at 19 hours than earlier, unlike a prior human study. Subcutaneous injection produced greater antagonism than intraperitoneal, consistent with higher brain levels. Sex differences likely stem from lower ibogaine bioavailability in males.

[125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex.

Pharmacology, biochemistry, and behavior January 1, 1990 M P Johnson, C A Mathis, A T Shulgin et al. 56 citations

A radiolabeled compound, [125I]-2C-I, was used to label low-density 5-HT2 agonist binding sites in brain tissue. The nonhydrolyzable GTP analog GppNHp inhibited high-affinity binding, and serotonin along with several 5-HT2 agonists and antagonists showed high affinity for the site. At 37°C, the number of binding sites (Bmax) decreased compared to 24°C, while binding affinity (KD) remained unchanged. Structure-activity relationships for displacing [125I]-2C-I supported the receptor's role in hallucinogen action. The findings demonstrate [125I]-2C-I as a useful radioligand and provide further evidence linking the 5-HT2 receptor to hallucinogenic activity.

Altered responses to serotonergic agents in Fawn-Hooded rats.

Pharmacology, biochemistry, and behavior March 1, 1985 G A Gudelsky, J I Koenig, H Y Meltzer 54 citations

Rats of the Fawn-Hooded (FH) strain show stronger behavioral responses to certain serotonin-related drugs compared to Sprague-Dawley (SD) rats. Specifically, FH rats exhibited significantly more "wet dog" shakes when given quipazine and a greater hyperthermic response to 5MeODMT. Conversely, the hypothermic effect of 8-OH-DPAT was significantly weaker in FH rats than in SD rats. These results suggest that central nervous system serotonergic mechanisms differ markedly between the two rat strains.

Initial characterization of PMMA as a discriminative stimulus.

Pharmacology, biochemistry, and behavior January 1, 1997 R A Glennon, R Young, M Dukat et al. 48 citations

The drug PMMA, a hybrid of PMA and methamphetamine, produces effects in rats similar to MDMA (Ecstasy) but lacks the stimulant or hallucinogen-like properties of amphetamine or DOM. Rats trained to distinguish PMMA from saline did not respond to amphetamine or DOM, but did respond to MDMA and its S(+) isomer. Partial responses occurred with several related compounds. These results suggest PMMA acts like MDMA without amphetamine-like stimulation, supporting the idea that PMMA is the structural parent of MDMA-like designer drugs.

Repeated administration of low doses of cocaine enhances the sensitivity of 5-HT2 receptor function.

Pharmacology, biochemistry, and behavior March 1, 1992 N A Darmani, B R Martin, R A Glennon 48 citations

Cocaine acutely suppresses a serotonin-related behavior in mice (the head-twitch response) by activating other receptors, not by blocking 5-HT3 receptors. During withdrawal from chronic cocaine treatment, the same behavior becomes enhanced, indicating supersensitivity that can last up to 172 hours depending on the cocaine dose. Low-dose chronic cocaine withdrawal increases the response to a selective 5-HT2 agonist, while higher doses do not. Withdrawal also increases the inhibitory effect of a 5-HT1A agonist on the behavior.

Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies.

Pharmacology, biochemistry, and behavior November 1, 1994 P A Broderick, F T Phelan, F Eng et al. 46 citations

Ibogaine reduced cocaine-induced increases in dopamine release in the nucleus accumbens and amplified cocaine-induced decreases in serotonin release in male rats. It also diminished cocaine-stimulated ambulation and central ambulation, behaviors that had habituated over time in the test chamber. Rearing and fine movements, which did not habituate, were not affected by ibogaine. Ibogaine alone did not significantly alter dopamine release over two hours but did increase serotonin release and acted as a weak psychostimulant. The findings highlight a modulatory role for serotonin in ibogaine-cocaine interactions and show ibogaine's efficacy when cocaine responses are reduced by environmental habituation.

Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.

Pharmacology, biochemistry, and behavior September 1, 2010 Bryan A Killinger, Mary M Peet, Lisa E Baker 41 citations

Salvinorin A, the active compound in Salvia divinorum, is an atypical hallucinogen that selectively binds to kappa opioid receptors and is structurally distinct from other opioids. In a drug discrimination study, 16 male rats trained to recognize either LSD or ketamine did not generalize to salvinorin A, meaning the rats did not treat it as similar to those hallucinogens. This supports evidence that salvinorin A is pharmacologically distinct from traditional hallucinogens like LSD and ketamine, offering a unique tool for studying the neurochemical mechanisms of hallucination.

Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses.

Pharmacology, biochemistry, and behavior August 1, 1989 J F Nash, H Y Meltzer, G A Gudelsky 40 citations

Repeated administration of 5-MeODMT (3 mg/kg, twice daily for 14 days) in animals reduced the hypothermia and corticosterone secretion caused by an acute challenge with the 5-HT1A agonist 8-OH-DPAT, compared to vehicle-treated animals. Chronic 5-MeODMT did not affect hyperthermia or corticosterone secretion from the 5-HT2 agonist MK-212. Repeated administration of DOI (1 mg/kg daily for 7 days) reduced corticosterone but not body temperature increases from MK-212, and did not alter responses to 8-OH-DPAT. These results suggest that chronic 5-MeODMT selectively reduces 5-HT1A receptor-mediated responses, while chronic DOI selectively reduces 5-HT2 receptor-mediated corticosterone secretion without affecting thermoregulatory responses, supporting the independence of these receptor systems.

Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus.

Pharmacology, biochemistry, and behavior February 1, 1998 S Helsley, D Fiorella, R A Rabin et al. 35 citations

In rats trained to recognize the hallucinogen ibogaine, two other hallucinogens—LSD and DOM—partially substituted for ibogaine (63% and 66.4% of responses, respectively). This partial substitution was completely blocked by the 5-HT2A antagonist pirenpirone, indicating that LSD and DOM produce ibogaine-like effects through the 5-HT2A receptor. However, pirenpirone did not block ibogaine itself or its effects from harmaline and noribogaine. Ibogaine, noribogaine, and harmaline showed only micromolar affinity for the 5-HT2A receptor (92.5, 34.5, and 42.5 µM). Ibogaine and harmaline, but not noribogaine, protected the receptor from alkylation. The findings suggest that while ibogaine interacts with 5-HT2A receptors, these interactions are not essential for its discriminative stimulus effects.

Opposite effects of intraventricular serotonin and bufotenin on rat startle responses.

Pharmacology, biochemistry, and behavior January 1, 1975 M A Geyer, J D Warbritton, D B Menkes et al. 34 citations

Rat startle responses to air puffs were measured during infusion of serotonin (5-HT), a hallucinogenic compound (5-HDMT), or saline. Serotonin reduced startle magnitude in a dose-dependent way, while the hallucinogen increased startle responses. Neither compound specifically affected sensitization or habituation. The findings suggest a central serotonin system that promotes behavioral inhibition, which indoleamine hallucinogens may oppose.

Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Pharmacology, biochemistry, and behavior April 1, 2016 Adam L Halberstadt 33 citations

Combining 5-MeO-DMT with monoamine oxidase inhibitors (MAOIs) changes how the drug affects behavior in rats. 5-MeO-DMT alone did not disrupt prepulse inhibition (PPI), a measure of sensorimotor gating, but when rats were pretreated with the MAO-A inhibitor clorgyline or the MAO-A/B inhibitor pargyline, the drug disrupted PPI. This disruption was blocked by antagonists of either 5-HT1A or 5-HT2A receptors, indicating both receptor types are involved. MAO-A inhibition increased levels of 5-MeO-DMT in plasma and whole brain but did not affect its conversion to bufotenine, which was negligible. The findings suggest that MAOIs enhance the drug's effects by increasing its accumulation in the central nervous system.